Concentration of circulating microparticles: a new biomarker of acute heart failure after cardiac surgery with cardiopulmonary bypass.
acute heart failure
biomarker
cardiopulmonary bypass
concentration
microparticles
Journal
Science China. Life sciences
ISSN: 1869-1889
Titre abrégé: Sci China Life Sci
Pays: China
ID NLM: 101529880
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
20
03
2020
accepted:
12
05
2020
pubmed:
18
6
2020
medline:
27
11
2021
entrez:
18
6
2020
Statut:
ppublish
Résumé
Acute heart failure (AHF) is a severe complication after cardiac surgery with cardiopulmonary bypass (CPB). Although some AHF biomarkers have been used in clinic, they have limitations when applied in the prediction and diagnosis of AHF after cardiac surgery with CPB, and there are still no effective and specific biomarkers. We and other researchers have shown that circulating microparticles (MPs) increased in a variety of cardiovascular diseases. However, whether the concentration of circulating MPs could be a new biomarker for AHF after cardiac surgery remains unknown. Here, 90 patients undergoing cardiac surgery with CPB and 45 healthy subjects were enrolled. Patients were assigned into AHF (n=14) or non-AHF (n=76) group according to the diagnosis criteria of AHF. The concentrations of circulating MPs were determined before, as well as 12 h and 3 days after operation with nanoparticle tracking analysis technique. MPs concentrations in patients before surgery were significantly higher than those of healthy subjects. Plasma levels of MPs were significantly elevated at 12 h after surgery in patients with AHF, but not in those without AHF, and the circulating MPs concentrations at 12 h after surgery were higher in AHF group compared with non-AHF group. Logistic regression analysis indicated that MPs concentration at postoperative 12 h was an independent risk factor for AHF. The area under receiver operating characteristic curve for MPs concentration at postoperative 12 h was 0.81 and the best cut-off value is 5.20×10
Identifiants
pubmed: 32548691
doi: 10.1007/s11427-020-1708-9
pii: 10.1007/s11427-020-1708-9
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-116Références
Bank, I.E.M., Timmers, L., Gijsberts, C.M., Zhang, Y.N., Mosterd, A., Wang, J.W., Chan, M.Y., De Hoog, V., Lim, S.K., Sze, S.K., et al. (2015). The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease. Expert Rev Mol Diagn 15, 15771588.
Berezin, A.E. (2016). Prognostication in different heart failure phenotypes: The role of circulating biomarkers. J Circ Biomark 5, 6.
pubmed: 28936254
pmcid: 5548324
Berezin, A.E. (2017). Microparticles in chronic heart failure. Adv Clin Chem 81, 1–41.
pubmed: 28629587
Berezin, A.E., Kremzer, A.A., Berezina, T.A., and Martovitskaya, Y.V. (2015a). Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation. BBA Clin 4, 69–75.
pubmed: 26674662
pmcid: 4661711
Berezin, A.E., Kremzer, A.A., Martovitskaya, Y.V., Samura, T.A., and Berezina, T.A. (2015b). The association of subclinical hypothyroidism and pattern of circulating endothelial-derived microparticles among chronic heart failure patients. Res Cardiovasc Med 4, 7.
Berezin, A.E., Kremzer, A.A., Samura, T.A., Berezina, T.A., and Kruzliak, P. (2015c). Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus. J Endocrinol Invest 38, 865–874.
pubmed: 25916429
Brouwers, F.P., de Boer, R.A., van der Harst, P., Voors, A.A., Gansevoort, R.T., Bakker, S.J., Hillege, H.L., van Veldhuisen, D.J., and van Gilst, W. H. (2013). Incidence and epidemiology of new onset heart failure with preserved v. reduced ejection fraction in a community-based cohort: 11-year follow-up of prevend. Eur Heart J 34, 1424–1431.
pubmed: 23470495
Burger, D., and Touyz, R.M. (2012). Cellular biomarkers of endothelial health: Microparticles, endothelial progenitor cells, and circulating endothelial cells. J Am Soc Hypertens 6, 85–99.
pubmed: 22321962
Burger, D., Schock, S., Thompson, C.S., Montezano, A.C., Hakim, A.M., and Touyz, R.M. (2013). Microparticles: Biomarkers and beyond. Clin Sci 124, 423–441.
Chow, S.L., Maisel, A.S., Anand, I., Bozkurt, B., de Boer, R.A., Felker, G. M., Fonarow, G.C., Greenberg, B., Januzzi Jr, J.L., Kiernan, M.S., et al. (2017). Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the american heart association. Circulation 135, e1054.
pubmed: 28446515
Ci, H.B., Ou, Z.J., Chang, F.J., Liu, D.H., He, G.W., Xu, Z., Yuan, H.Y., Wang, Z.P., Zhang, X., and Ou, J.S. (2013). Endothelial microparticles increase in mitral valve disease and impair mitral valve endothelial function. Am J Physiol Endocrinol Metab 304, E695–E702.
pubmed: 23384770
Coumans, F.A.W., Brisson, A.R., Buzas, E.I., Dignat-George, F., Drees, E.E.E., El-Andaloussi, S., Emanueli, C., Gasecka, A., Hendrix, A., Hill, A.F., et al. (2017). Methodological guidelines to study extracellular vesicles. Circ Res 120, 1632–1648.
pubmed: 28495994
Das, S., and Halushka, M.K. (2015). Extracellular vesicle microRNA transfer in cardiovascular disease. Cardiovasc Pathol 24, 199–206.
pubmed: 25958013
Delcayre, C., and Swynghedauw, B. (2002). Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 34, 1577–1584.
pubmed: 12505056
Densmore, J.C., Signorino, P.R., Ou, J., Hatoum, O.A., Rowe, J.J., Shi, Y., Kaul, S., Jones, D.W., Sabina, R.E., Pritchard Jr, K.A., et al. (2006). Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock 26, 464–471.
pubmed: 17047516
Dignat-George, F., and Boulanger, C.M. (2011). The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 31, 27–33.
pubmed: 21160065
Dragovic, R.A., Gardiner, C., Brooks, A.S., Tannetta, D.S., Ferguson, D.J. P., Hole, P., Carr, B., Redman, C.W.G., Harris, A.L., Dobson, P.J., et al. (2011). Sizing and phenotyping of cellular vesicles using nanoparticle tracking analysis. Nanomedicine 7, 780–788.
pubmed: 21601655
pmcid: 3280380
Feng, Y.L., and Yu, X.Y. (2011). Cardinal roles of miRNA in cardiac development and disease. Sci China Life Sci 54, 1113–1120.
pubmed: 22227903
Fu, L., Hu, X.X., Lin, Z.B., Chang, F.J., Ou, Z.J., Wang, Z.P., and Ou, J.S. (2015). Circulating microparticles from patients with valvular heart disease and cardiac surgery inhibit endothelium-dependent vasodilation. J Thorac Cardiovasc Surg 150, 666–672.
pubmed: 26145768
Gong, J., Jaiswal, R., Dalla, P., Luk, F., and Bebawy, M. (2015). Microparticles in cancer: A review of recent developments and the potential for clinical application. Semin Cell Dev Biol 40, 35–40.
pubmed: 25843775
Greening, D.W., Gopal, S.K., Mathias, R.A., Liu, L., Sheng, J., Zhu, H.J., and Simpson, R.J. (2015). Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression. Semin Cell Dev Biol 40, 60–71.
pubmed: 25721809
Heart Failure Group of Chinese Society of Cardiology of Chinese Medical, A. Chinese Heart Failure Association of Chinese Medical Doctor, A., and Editorial Board of Chinese Journal Of, C. (2018). Chinese guidelines for the diagnosis and treatment of heart failure 2018. Chin J Cardiovasc Dis 46, 760–789.
Jian, Y.P., Yuan, H.X., Hu, K.H., Chen, C., Li, Y.Q., Li, Y., Yang, T.X., Ou, Z.J., and Ou, J.S. (2019). Protein compositions changes of circulating microparticles in patients with valvular heart disease subjected to cardiac surgery contribute to systemic inflammatory response and disorder of coagulation. Shock 52, 487–496.
pubmed: 30601407
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J.P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., and Théry, C. (2016). Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci USA 113, E968–E977.
pubmed: 26858453
Levy, D., Kenchaiah, S., Larson, M.G., Benjamin, E.J., Kupka, M.J., Ho, K.K.L., Murabito, J.M., and Vasan, R.S. (2002). Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347, 13971402.
Lin, Z.B., Ci, H.B., Li, Y., Cheng, T.P., Liu, D.H., Wang, Y.S., Xu, J., Yuan, H.X., Li, H.M., Chen, J., et al. (2017). Endothelial microparticles are increased in congenital heart diseases and contribute to endothelial dysfunction. J Transl Med 15, 4.
pubmed: 28049487
pmcid: 5210308
Liu, Y., He, Z., Zhang, Y., Dong, Z., Bi, Y., Kou, J., Zhou, J., and Shi, J. (2016). Dissimilarity of increased phosphatidylserine-positive microparticles and associated coagulation activation in acute coronary syndromes. Coron Artery Dis 27, 365–375.
pubmed: 27058313
Mahmoud, A.M., Wilkinson, F.L., McCarthy, E.M., Moreno-Martinez, D. M., Langford-Smith, A., Romero, M., Duarte, J., and Alexander, M.Y. (2017). Endothelial microparticles prevent lipid-induced endothelial damage via Akt/eNOS signaling and reduced oxidative stress. FASEB J 31, 4636–4648.
pubmed: 28687612
pmcid: 5714503
Martinez, M.C., and Andriantsitohaina, R. (2011). Microparticles in angiogenesis. Circ Res 109, 110–119.
pubmed: 21700952
Nichols, M., Townsend, N., Scarborough, P., and Rayner, M. (2014). Cardiovascular disease in europe 2014: Epidemiological update. Eur Heart J 35, 2950–2959.
pubmed: 25139896
Ou, Z.J., Chang, F.J., Luo, D., Liao, X.L., Wang, Z.P., Zhang, X., Xu, Y.Q., and Ou, J.S. (2011). Endothelium-derived microparticles inhibit angiogenesis in the heart and enhance the inhibitory effects of hypercholesterolemia on angiogenesis. Am J Physiol Endocrinol Metab 300, E661–E668.
pubmed: 21245463
Peng, L.N., Li, Y.J., Zhang, L., and Yu, W.Q. (2013). Moving RNA moves RNA forward. Sci China Life Sci 56, 914–920.
pubmed: 24008386
Peterson, D.B., Sander, T., Kaul, S., Wakim, B.T., Halligan, B., Twigger, S., Pritchard Jr., K.A., Oldham, K.T., and Ou, J.S. (2008). Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles. Proteomics 8, 2430–2446.
pubmed: 18563738
pmcid: 4753841
Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G.F., Coats, A.J.S., Falk, V., González-Juanatey, J.R., Harjola, V.P., Jankowska, E.A., et al. (2016). 2016 esc guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 18, 891–975.
pubmed: 27207191
Rohde, L.E., Bertoldi, E.G., Goldraich, L., and Polanczyk, C.A. (2013). Cost-effectiveness of heart failure therapies. Nat Rev Cardiol 10, 338354.
Saari, H., Lázaro-Ibáñez, E., Viitala, T., Vuorimaa-Laukkanen, E., Siljander, P., and Yliperttula, M. (2015). Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells. J Control Release 220, 727–737.
pubmed: 26390807
Sander, T.L., Ou, J.S., Densmore, J.C., Kaul, S., Matus, I., Twigger, S., Halligan, B., Greene, A.S., Pritchard, K.A., and Oldham, K.T. (2008). Protein composition of plasminogen activator inhibitor type 1-derived endothelial microparticles. Shock 29, 504–511.
pubmed: 18598005
Souza, A.C.P., Yuen, P.S.T., and Star, R.A. (2015). Microparticles: Markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI. Kidney Int 87, 1100–1108.
pubmed: 25692956
pmcid: 4449806
Ural, D., Çavuşoğlu, Y., Eren, M., Karaüzüm, K., Temizhan, A., Yilmaz, M.B., Zoghi, M., Ramassubu, K., and Bozkurt, B. (2015). Diagnosis and management of acute heart failure. Anatol J Cardiol 15, 860889.
Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey Jr., D.E., Drazner, M.H., Fonarow, G.C., Geraci, S.A., Horwich, T., Januzzi, J.L., et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol 62, e147–e239.
pubmed: 23747642
Zhang, X., Liu, H., Gao, J., Zhu, M., Wang, Y., Jiang, C., and Xu, M. (2019). Metabolic disorder in the progression ofheart failure. Sci China Life Sci 62, 1153–1167.
pubmed: 31187303
Zhou, K., and Hong, T. (2017). Cardiac BIN
pubmed: 27888388